TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$345 Million

Vir Biotechnology, Inc.

Follow-on Offering

Bookrunner, July 2020

Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The Company has assembled four technology platforms, focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid, or siRNA. The Company’s current development pipeline consists of product candidates targeting severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, the virus that causes COVID-19, hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB.